Last updated: August 5, 2026
Bosutinib monohydrate is the active pharmaceutical ingredient in Pfizer’s Bosulif tablets, an oral BCR-ABL tyrosine kinase inhibitor for Philadelphia chromosome-positive chronic myeloid leukemia. The product has developed into a durable, approximately $1 billion annual global franchise, supported by expanded-line treatment use, long-term physician familiarity, and limited direct competition in certain resistant or intolerant CML patients.
The main commercial risk is loss of exclusivity. Bosutinib competes against lower-cost generic imatinib, dasatinib, and nilotinib, while newer agents such as asciminib target the same CML treatment market. Bosulif’s revenue trajectory depends on retaining patients in later-line therapy, maintaining branded reimbursement, and delaying meaningful generic substitution through patent and regulatory protections.
What is bosutinib monohydrate and how is it used?
Bosutinib monohydrate is the monohydrate form of bosutinib, a selective inhibitor of BCR-ABL and Src-family kinases. Bosulif is supplied as oral film-coated tablets in 100 mg, 400 mg, and 500 mg strengths in the United States. The standard adult starting dose is generally 400 mg once daily for newly diagnosed chronic-phase CML and 500 mg once daily for resistant or intolerant disease, subject to dose modifications for toxicity. [1]
The approved U.S. indications are:
| Indication |
Treatment setting |
| Newly diagnosed Philadelphia chromosome-positive chronic-phase CML |
First-line treatment |
| Philadelphia chromosome-positive chronic-, accelerated-, or blast-phase CML |
Resistant or intolerant disease after prior therapy |
The principal adverse-event liabilities are diarrhea, nausea, rash, liver enzyme elevations, and cytopenias. Diarrhea and gastrointestinal toxicity can affect treatment persistence, while hepatic monitoring adds clinical-management requirements. [1]
What is the difference between bosutinib and bosutinib monohydrate?
Bosutinib monohydrate is the solid-state form used in the pharmaceutical product. Marketed demand is reported under Bosulif or bosutinib rather than as a separate commercial category for the monohydrate API. API manufacturers, generic developers, and contract manufacturers must reproduce or appropriately control the relevant solid form, particle characteristics, impurity profile, and dissolution performance.
What is the FDA regulatory status of Bosulif?
Bosulif received U.S. FDA approval in 2012 for adults with Philadelphia chromosome-positive CML whose disease was resistant or intolerant to prior therapy. FDA later expanded the label to include newly diagnosed chronic-phase CML. [2]
| Regulatory event |
Date |
| Initial FDA approval |
September 2012 |
| Newly diagnosed chronic-phase CML indication |
December 2017 |
| U.S. dosage forms |
100 mg, 400 mg, 500 mg tablets |
| Regulatory pathway |
New drug application |
| Reference product |
Bosulif, Pfizer |
| Active ingredient |
Bosutinib monohydrate |
The product is also authorized in the European Union as Bosulif. The European Medicines Agency approved bosutinib for adult patients with Philadelphia chromosome-positive CML in chronic, accelerated, or blast phase who had prior therapy or newly diagnosed chronic-phase disease when other treatments are considered inappropriate. [3]
Bosulif is not a biologic. Biosimilar regulation therefore does not apply. Competitive entry will occur through abbreviated new drug applications, generic marketing authorizations, and pharmaceutical-equivalence requirements rather than through the biosimilar pathway.
How has Pfizer’s Bosulif revenue changed?
Pfizer’s public financial reporting indicates that Bosulif has grown from a specialty oncology product into a material global revenue contributor. The product benefited from label expansion, increased use in earlier treatment lines, and continued demand for an oral option after intolerance or inadequate response to other TKIs.
| Fiscal year |
Reported Bosulif revenue |
| 2020 |
Approximately $730 million |
| 2021 |
Approximately $850 million |
| 2022 |
Approximately $920 million |
| 2023 |
Approximately $1.0 billion |
| 2024 |
Approximately $1.0 billion |
Source figures are based on Pfizer annual reports and product-revenue disclosures; currency translation and reporting-period differences affect year-to-year comparisons. [4,5]
The commercial pattern is important. Bosulif revenue expanded after the initial launch period but is now closer to a mature-franchise profile than a high-growth launch profile. The product’s base is supported by:
- use in newly diagnosed chronic-phase CML;
- switching after intolerance to imatinib, dasatinib, or nilotinib;
- treatment of resistant disease;
- long-term oral therapy and specialist prescribing;
- availability across the United States, Europe, and other international markets.
The revenue base remains exposed to generic erosion because CML treatment is chronic, price-sensitive, and clinically substitutable in several treatment lines.
What drives demand for bosutinib in the CML market?
Bosutinib occupies a differentiated but competitive position in a mature CML market. Imatinib remains the lowest-cost anchor after generic entry. Dasatinib and nilotinib have broad physician familiarity and established use in first-line and later-line treatment. Ponatinib is used particularly where resistant mutations, including T315I, create a need for a more potent inhibitor. Asciminib provides an allosteric mechanism and has become a major competitive threat in previously treated patients.
How does bosutinib compare with competing CML drugs?
| Drug |
Mechanism |
Commercial position |
Main competitive effect on Bosulif |
| Imatinib |
ATP-competitive BCR-ABL inhibitor |
Low-cost generic standard |
Limits first-line pricing |
| Dasatinib |
BCR-ABL and Src-family inhibitor |
Generic and established brand |
Competes in first- and later-line therapy |
| Nilotinib |
BCR-ABL inhibitor |
Generic competition and established efficacy |
Reduces switching opportunity |
| Ponatinib |
Broad-spectrum BCR-ABL inhibitor |
Higher-risk, mutation-focused therapy |
Competes in resistant disease |
| Asciminib |
Allosteric BCR-ABL inhibitor |
Newer branded option |
Challenges later-line Bosulif use |
| Bosutinib |
BCR-ABL and Src-family inhibitor |
Branded, established oral therapy |
Retains value in intolerance and resistance settings |
Bosutinib’s strongest commercial position is among patients who need a switch because of intolerance or inadequate response to prior TKIs. Its weaker position is a newly diagnosed patient population where generic imatinib and generic second-generation TKIs create substantial price pressure.
When does bosutinib lose exclusivity?
Bosulif’s commercial exclusivity is controlled by several separate protections:
- New chemical entity exclusivity.
- Orphan-drug exclusivity for relevant CML indications.
- Listed patents covering bosutinib, formulations, and methods of use.
- Pediatric exclusivity, where applicable.
- Regulatory approval timing for generic applicants.
The five-year U.S. new chemical entity exclusivity period ended in 2017. Orphan exclusivity attached to the applicable approved indications also has expired. The remaining barrier is therefore patent protection and any applicable regulatory delay.
The earliest small-molecule patent protection is generally the key date for generic planning. Public patent databases and FDA Orange Book records should be read together because Orange Book-listed patents can include drug-substance, formulation, and method-of-use claims with different expiration dates. Patent-term adjustment, patent-term extension, pediatric exclusivity, and litigation settlements can change the practical launch date. [6]
What patents protect Bosulif?
Bosulif’s U.S. patent estate has historically included claims directed to:
| Patent category |
Commercial relevance |
| Bosutinib compound and salt forms |
Protects the active pharmaceutical ingredient |
| Monohydrate or solid-state forms |
Can restrict manufacture of the marketed form |
| Pharmaceutical compositions |
Covers tablets, excipients, and dosage presentation |
| Treatment of CML |
May support method-of-use listings |
| Dosing and patient-selection methods |
Can create narrower barriers after compound expiry |
| Manufacturing and purification processes |
Raises API-development and supply-chain risk |
The compound patent is generally the most valuable asset because it can block broad generic commercialization. Formulation and method-of-use patents are narrower. They can delay or complicate entry but may not prevent a generic applicant from launching with a label that omits protected indications or uses a non-infringing formulation.
Exact live patent status should be determined from the current Orange Book listing, issued patent records, terminal disclaimers, and any litigation docket. The existence of a listed patent does not establish that every claim will survive invalidity or non-infringement challenges. [6,7]
What is the Orange Book status of Bosulif?
Bosulif is an FDA-approved small-molecule reference product and is eligible for Orange Book listing. FDA’s Orange Book identifies approved drug products, therapeutic-equivalence information, and patents or exclusivity information submitted by the reference-product sponsor. [6]
An ANDA applicant can challenge listed patents through:
- Paragraph IV certification, asserting that a patent is invalid, unenforceable, or not infringed;
- Paragraph III certification, accepting delayed approval until patent expiry;
- a section viii statement, carving out a patented method of use from the generic label;
- a non-infringement strategy based on a different formulation or manufacturing process.
The practical generic-entry date depends on which patents are challenged, when Pfizer files suit, whether a 30-month stay applies, and whether the parties settle.
Which companies are challenging Bosulif patents?
Public generic competition can arise from major ANDA developers, specialty generic companies, and regional manufacturers. FDA approval of a generic does not always produce immediate commercial launch. A company may hold approval while resolving supply, patent, pricing, or distribution issues.
The public record does not establish a single, universally recognized Bosulif challenger with a confirmed nationwide U.S. commercial launch that has displaced Pfizer’s product. Generic applicants may remain confidential before litigation, and ANDA approvals can occur without a high-profile federal patent case.
What is the Paragraph IV risk for Bosulif?
Paragraph IV risk is moderate to high over the long term because:
- the product is a small molecule;
- bosutinib tablets are technically feasible to reproduce;
- CML treatment has a substantial generic substitution base;
- the brand generates approximately $1 billion in annual sales;
- multiple listed patents may create several challenge targets;
- a generic applicant can potentially use a label carve-out for method-of-use claims.
The risk is lower before the earliest enforceable compound or composition patent expires. It increases sharply when the principal barrier expires, particularly if multiple generic applicants obtain tentative or final approval.
What generic launch scenarios exist for bosutinib?
Scenario 1: Delayed entry after patent expiry
This is the least disruptive scenario for Pfizer before the first major patent expiry. Pfizer retains brand pricing while generic applicants wait for approval or resolve patent disputes.
Scenario 2: One authorized or licensed generic
Pfizer could license a generic distributor or launch an authorized generic. This would reduce the incentive for an independent generic challenger but would also transfer part of the product’s volume to a lower-priced channel.
Scenario 3: First generic launch with limited competition
A first entrant could capture a large share of prescriptions while maintaining relatively high generic pricing. The brand would likely retain patients with physician preference, specialty-pharmacy continuity, or payer restrictions.
Scenario 4: Multiple generic entrants
Several approved generics would produce the fastest price erosion. Chronic oral oncology products can experience substantial discounts once payers and specialty pharmacies place generics on preferred tiers.
Scenario 5: At-risk launch
A generic company could launch before final patent resolution if it accepts potential damages or injunction risk. This scenario would create the greatest downside for Pfizer but depends on the perceived strength of the asserted patents and the commercial value of early entry.
How strong is the Bosulif patent estate?
The estate is commercially meaningful but not uniformly strong across all claim types.
| Patent layer |
Relative strength |
Reason |
| Core compound claims |
High value, potentially strong |
Broadest exclusion of bosutinib products |
| Monohydrate or solid-state claims |
Medium to high |
Relevant to API and product reproducibility |
| Tablet formulation claims |
Medium |
Generic developers may design around claims |
| Method-of-use claims |
Medium to low |
Label carve-outs may reduce scope |
| Manufacturing claims |
Medium |
Can force alternate processes but rarely block all supply |
| Late-filed dosing claims |
Variable |
Narrower claims may face validity challenges |
The most important legal question is whether a generic applicant must use the protected monohydrate form to meet pharmaceutical-equivalence and dissolution requirements. If alternative solid forms or processes can achieve the same product specifications without infringing valid claims, formulation patents will provide less protection.
What licensing deals affect bosutinib?
Pfizer acquired rights to bosutinib through its acquisition of Wyeth, which had obtained the compound through the acquisition of Genetics Institute. The product is therefore commercially controlled by Pfizer rather than by a recently licensed biotechnology partner.
No major current co-commercialization transaction appears to define Bosulif’s global economics. Regional commercialization, distribution, and manufacturing arrangements may exist, but they do not change Pfizer’s central exposure to product-level generic erosion.
What patent litigation affects Bosulif?
Bosulif litigation risk is concentrated in ANDA patent cases under the Hatch-Waxman Act. The critical litigation questions are:
- whether asserted compound or formulation claims are valid;
- whether the generic product infringes the listed patents;
- whether method-of-use claims can be avoided through label carving;
- whether Pfizer has sued within the statutory period after receiving a Paragraph IV notice;
- whether the parties enter a launch-date settlement.
A settlement can establish an agreed generic-entry date before patent expiry. The commercial value of such a settlement depends on the number of challengers, the remaining patent term, and whether the agreement permits an authorized generic.
What manufacturing and intellectual-property barriers affect bosutinib?
Bosutinib manufacturing is less technically complex than biologic production but still presents material development requirements. A generic supplier must control:
- the bosutinib monohydrate solid form;
- polymorph and hydrate conversion;
- particle-size distribution;
- residual solvents and genotoxic impurities;
- tablet dissolution;
- stability under humidity and temperature stress;
- bioequivalence across relevant dosage strengths.
The monohydrate form can create a meaningful API-sourcing issue if a generic developer lacks a reliable supplier or must establish an alternative crystallization process. It is unlikely to constitute a permanent barrier for well-capitalized generic manufacturers, but it can raise development cost and delay entry.
Geographically, patent and regulatory barriers differ. U.S. entry is governed by the Orange Book and Hatch-Waxman litigation. European entry depends on national validation, supplementary protection certificates, national patent litigation, and local reimbursement. Emerging markets may experience earlier competition where patent enforcement is weaker or product registration follows different standards.
What is the revenue exposure to generic entry?
At approximately $1 billion in annual revenue, Bosulif is a meaningful but not transformational asset within Pfizer’s portfolio. Its exposure is concentrated in a chronic-treatment market, which increases the value of recurring prescriptions but also makes substitution easier once a lower-cost equivalent is approved.
A practical erosion framework is:
| Entry pattern |
Expected brand impact |
| No generic for 12 months after core expiry |
Revenue remains relatively stable |
| One generic entrant |
Moderate volume and price erosion |
| Two to three entrants |
Significant net-price decline |
| Broad generic competition |
Rapid loss of branded volume and reimbursement leverage |
| Authorized generic plus independent entrants |
Faster price compression, with partial retained economics for Pfizer |
The decline will likely occur through both price and volume. Specialty pharmacies and payers can shift patients quickly when the generic has equivalent dosage forms and the indication remains clinically interchangeable.
How does bosutinib compare with asciminib commercially?
Asciminib has a newer mechanism and stronger differentiation in patients who have exhausted multiple ATP-competitive TKIs. It is also positioned as a premium branded product. Bosutinib remains more established and may be preferred where physicians have experience managing its adverse-event profile or where payer access favors it.
Asciminib creates the greatest competitive pressure in later-line therapy. Generic imatinib, dasatinib, and nilotinib create the greatest pricing pressure in earlier treatment lines. Bosulif’s commercial defense is therefore based on treatment sequencing, tolerability-based switching, physician familiarity, and access rather than on exclusive mechanism alone.
Key Takeaways
- Bosutinib monohydrate is the active ingredient in Pfizer’s Bosulif tablets.
- Bosulif is approved for newly diagnosed and previously treated Philadelphia chromosome-positive CML.
- Pfizer’s annual Bosulif revenue reached approximately $1 billion by 2023-2024.
- New chemical entity and orphan exclusivity have expired; patent protection is the main remaining barrier.
- Orange Book patents may cover the compound, monohydrate form, formulations, manufacturing, and methods of use.
- Generic risk is structurally high because bosutinib is an oral small molecule used in chronic therapy.
- Generic imatinib, dasatinib, and nilotinib constrain pricing, while asciminib pressures later-line branded demand.
- A first generic could cause moderate erosion; multiple generic entrants would create substantially faster price compression.
- Bosulif is not subject to biosimilar competition.
- The monohydrate solid form and impurity-control requirements create development friction but are unlikely to block capable generic manufacturers permanently.
FAQs About Bosutinib Monohydrate and Bosulif
Is bosutinib monohydrate the same as Bosulif?
Bosutinib monohydrate is the active pharmaceutical ingredient used in Bosulif. Bosulif is the Pfizer-branded finished tablet product.
Is bosutinib a biologic or a small-molecule drug?
Bosutinib is an orally administered small-molecule kinase inhibitor. Generic, not biosimilar, competition applies.
What cancer does bosutinib treat?
Bosutinib treats Philadelphia chromosome-positive chronic myeloid leukemia, including newly diagnosed chronic-phase disease and resistant or intolerant chronic-, accelerated-, or blast-phase disease.
Can a generic bosutinib omit protected indications?
Yes. An ANDA applicant may use a section viii statement or a label carve-out for certain patented methods of use, provided the remaining label complies with FDA requirements.
What is the largest commercial threat to Bosulif?
The largest near-term commercial threats are generic entry after patent protection weakens, payer substitution to generic second-generation TKIs, and asciminib use in patients receiving later-line treatment.
